Search Results

You are looking at 31 - 40 of 135 items for :

Clear All
Full access

Ellin Berman

halted. Patients with the T315I mutation or who had no other tyrosine kinase inhibitor (TKI) option required a single-patient Investigational New Drug (IND) approval from the FDA to receive the drug. Ponatinib was re-released in December 2013, with

Full access

Matthew P. Banegas, Donna R. Rivera, Maureen C. O’Keeffe-Rosetti, Nikki M. Carroll, Pamala A. Pawloski, David C. Tabano, Mara M. Epstein, Kai Yeung, Mark C. Hornbrook, Christine Lu and Debra P. Ritzwoller

improvements in prognosis, with a 50% decrease in the mortality rate from 2000 to 2015. 2 The life expectancy of patients with CML is approaching that of the general population. 3 Imatinib, an orally administered tyrosine kinase inhibitor (TKI), was approved

Full access

Philip E. Lammers and Leora Horn

, phosphatidylinositol-3-kinase; RAF, v-raf 1 murine leukemia viral oncogene homolog 1; RAS, retrovirus-associated DNA sequences; RET, rearranged during transfection; SRC, v-src sarcoma viral oncogene homolog; TKIs, tyrosine kinase inhibitors; VEGF, vascular endothelial

Full access

George D. Demetri, Margaret von Mehren, Cristina R. Antonescu, Ronald P. DeMatteo, Kristen N. Ganjoo, Robert G. Maki, Peter W.T. Pisters, Chandrajit P. Raut, Richard F. Riedel, Scott Schuetze, Hema M. Sundar, Jonathan C. Trent and Jeffrey D. Wayne

117) or platelet-derived growth factor receptor alpha (PDGFRA). The standard of care in the management of patients with GIST rapidly changed after the introduction of tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate

Full access

Jorge Cortes, Clara Chen, Michael Mauro, Neela Kumar, Catherine Davis and Stuart L. Goldberg

tyrosine kinase inhibitor (TKI) use in routine clinical practice among CP-CML pts receiving TKIs in the US and Europe since 2010. This analysis reports NIL dosing patterns and explores predictors of dose reductions. A subset analysis focusing on the first

Full access

Victoria Crossland, Aaron Galaznik, Huamao M. Lin, Dimitrios Tomaras, Shan Ashton Garib, Shuanglian Li, Hui Huang and Anna Forsythe

Background: Epidermal growth factor receptor (EGFR) mutations are frequently found in non-small cell lung cancer (NSCLC) patients. Various EGFR mutations respond differently to EGFR tyrosine kinase inhibitors (TKIs), and several TKIs have been

Full access

Jay Gong, Jeffrey P. Gregg, Weijie Ma, Ken Yoneda, Elizabeth H. Moore, Megan E. Daly, Yanhong Zhang, Melissa J. Williams and Tianhong Li

). 2 , 3 FDA approval of crizotinib, a small molecule ALK tyrosine kinase inhibitor (TKI), only 3 years after the discovery of the ALK fusion oncogene represents one of the most rapid bench-to-bedside translational advances in the history of targeted

Full access

Javier Pinilla-Ibarz and Alfonso Quintás-Cardama

failure to multiple TKI therapies or with T315I mutation [abstract] . Blood 2008 ; 112 : Abstract 3232 . 67 Paquette RL Shah NP Sawyers CL . PHA-739358, an Aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia

Full access

Tarek Haykal, Babikir Kheiri, Varun Samji, Yazan Zayed, Ragheed Al-Dulaimi, Inderdeep Gakhal, Areeg Bala, Jason Sotzen, Ahmed Abdalla and Ghassan Bachuwa

metastatic RCC. Despite the proven efficacy of sunitinib, prolonged treatment with some tyrosine kinase inhibitors (TKIs) has been associated with significant adverse events (AEs). Therefore, we aimed to calculate the exact prevalence of all sunitinib

Full access

Balazs Halmos, Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A. Soo, James C-H Yang, Rasim Gucalp, Lara Wang, Angela Märten and Tanja Cufer

Background: EGFR TKIs have shown first-line efficacy in EGFR m+ NSCLC but acquired resistance is inevitable; with afatinib, this is predominantly through the emergence of T790M. Therefore, a key consideration when assessing therapeutic choices is